Tymlos: CE Certification for Osteoporosis Treatment | Learn More

Hybio Pharmaceutical Co., Ltd. is proud to present Tymlos, a breakthrough treatment for osteoporosis that has obtained CE Certification. Tymlos is designed to reduce the risk of fractures in postmenopausal women with osteoporosis who are at high risk for fracture, The drug contains the active ingredient abaloparatide, a synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein). Tymlos works by stimulating bone formation, increasing bone mass, and improving bone strength, ultimately reducing the risk of fractures, With the CE Certification, Tymlos has met the rigorous safety, health, and environmental protection standards within the European Economic Area. This certification demonstrates our commitment to delivering safe and effective treatments to patients suffering from osteoporosis, Hybio Pharmaceutical Co., Ltd. is dedicated to improving the quality of life for those affected by osteoporosis, and Tymlos is a testament to our ongoing efforts in developing innovative and reliable treatments for this debilitating condition